Microtech has commenced human clinical trials of its implantable microsensor platform, aimed at measuring atrial pressures critical in managing heart failure.
Prof Erez Sharoni of Beilinson Medical Center in Petah-Tikva, Israel performed the first implantation procedure.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Representing years of research and development, the microsensor platform can function as a standalone device or be integrated into existing medical devices.
Its sub-millimetre size, ultrasound communication, and ‘passive’ operation enable the conversion of traditional implants into smart devices, ‘enhancing’ their capability to collect and relay multiple data points simultaneously.
The technology allows patients with Microtech-enabled implants to transmit ‘precise’ pressure readings directly to their physicians using a compact home unit, facilitating immediate and accurate monitoring. Heart Failure specialists will utilise the data collected by these sensors to refine clinical decision-making for patients.
The Microtech sensors are compatible with a range of present-day implants, from structural heart devices to cardiac rhythm management (CRM) devices without interfering with their primary functions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPart of Medinol, Microtech claims to have multidisciplinary development teams and extensive regulatory and clinical expertise.
Medinol CEO Dr Yoram Richter said: “Incorporating sensors into existing medical devices gives physicians the ability to treat patients based on quantifiable physiological parameters instead of symptoms and is a critical step to growing access to equitable healthcare across the global community.
“This unique ability is transformative for a wide range of clinical scenarios, including patients suffering from Heart Failure, Glaucoma, Hydrocephalous, Portal Hypertension, AAA Endoleaks, and many more, providing wider healthcare access and fewer office/hospital visits.
“Most importantly, from the standpoint of treating clinicians and device manufacturers, sensor-enabled smart-devices will go beyond acute anatomical fixes, extending treatment to lifetime patient care.”
In addition to cardiology, the company’s technology is undergoing preclinical studies across various medical fields, including neurology, vascular studies, and ophthalmology.
